LeonaBio, Inc.

NasdaqCM:LONA Stock Report

Market Cap: US$94.3m

LeonaBio Future Growth

Future criteria checks 0/6

LeonaBio is forecast to grow earnings and revenue by 3.9% and 75.7% per annum respectively while EPS is expected to grow by 50.6% per annum.

Key information

3.9%

Earnings growth rate

50.59%

EPS growth rate

Pharmaceuticals earnings growth14.5%
Revenue growth rate75.7%
Future return on equityn/a
Analyst coverage

Low

Last updated08 May 2026

Recent future growth updates

Recent updates

Analysis Article • Feb 16

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 02

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 29

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 04

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 17

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma (NASDAQ:ATHA) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an interim efficacy and futility analysis of the study, dubbed LIFT-AD, the company added. In addition, the panel decided that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 people without background therapy (acetylcholinesterase inhibitors), the trial will be well powered for the main goal given the preliminary effect size seen, according to the company. The main goal of the trial is Global Statistical Test, a tool for measuring cognition and function. Athira noted that data from a phase 2 study called ACT-AD had showed a favorable safety profile and suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton without background therapy. ATHA +2.49% to $3.29 premarket Oct. 17
Seeking Alpha • Aug 15

Athira Pharma GAAP EPS of -$0.65

Athira Pharma press release (NASDAQ:ATHA): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021.
Analysis Article • Aug 09

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 22

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen. The company's shares are falling severely on the primary endpoint miss. Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.
Analysis Article • May 08

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jan 11

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.
Analysis Article • May 24

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Feb 08

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 18

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

The big shareholder groups in Athira Pharma, Inc. ( NASDAQ:ATHA ) have power over the company. Institutions often own...

Earnings and Revenue Growth Forecasts

NasdaqCM:LONA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-141-135N/A2
12/31/2027N/A-119-112N/A2
12/31/2026N/A-115-88N/A3
3/31/2026N/A-129-52-52N/A
12/31/2025N/A-106-46-46N/A
9/30/2025N/A-38-52-52N/A
6/30/2025N/A-60-71-71N/A
3/31/2025N/A-80-86-86N/A
12/31/2024N/A-97-97-97N/A
9/30/2024N/A-109-97-97N/A
6/30/2024N/A-113-98-98N/A
3/31/2024N/A-116-100-100N/A
12/31/2023N/A-118-101-101N/A
9/30/2023N/A-121-90-90N/A
6/30/2023N/A-108-88-88N/A
3/31/2023N/A-102-83-82N/A
12/31/2022N/A-96-74-72N/A
9/30/2022N/A-82-77-75N/A
6/30/2022N/A-77-66-64N/A
3/31/2022N/A-67-54-52N/A
12/31/2021N/A-55-45-43N/A
9/30/2021N/A-46-38-36N/A
6/30/2021N/A-39-37-35N/A
3/31/2021N/A-27-33-30N/A
12/31/2020N/A-20-26-24N/A
9/30/2020N/A-13-15-14N/A
6/30/2020N/A-6-6-6N/A
3/31/2020N/A-6-4-4N/A
12/31/2019N/A-5N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LONA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LONA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LONA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LONA is forecast to have no revenue next year.

High Growth Revenue: LONA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LONA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 16:18
End of Day Share Price 2026/05/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LeonaBio, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Eric SchmidtCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC